S Schneeweiss

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis
    Sebastian Schneeweiss
    Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA 021205, USA
    Arthritis Rheum 54:3390-8. 2006
  2. ncbi Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Geriatr Soc 53:948-54. 2005
  3. ncbi A review of uses of health care utilization databases for epidemiologic research on therapeutics
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 58:323-37. 2005
  4. ncbi Aprotinin during coronary-artery bypass grafting and risk of death
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    N Engl J Med 358:771-83. 2008
  5. ncbi Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Epidemiology 16:17-24. 2005
  6. ncbi Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Psychopharmacol 24:632-8. 2004
  7. ncbi A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 58:98-102. 2005
  8. ncbi Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    Med Care 42:653-60. 2004
  9. ncbi Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations
    Sebastian Schneeweiss
    Brigham and Women s Hospital and Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, 1620 Tremont St Suite 3030, Boston, MA 02120, USA
    BMJ 328:560. 2004
  10. ncbi Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Med Care 45:S131-42. 2007

Collaborators

Detail Information

Publications114 found, 100 shown here

  1. ncbi Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis
    Sebastian Schneeweiss
    Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA 021205, USA
    Arthritis Rheum 54:3390-8. 2006
    ....
  2. ncbi Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Geriatr Soc 53:948-54. 2005
    ..To identify the magnitude of confounding bias caused by factors not measured in claims data studies of sedative-hypnotic use and fractures...
  3. ncbi A review of uses of health care utilization databases for epidemiologic research on therapeutics
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 58:323-37. 2005
    ..However, concerns about database studies include data validity, lack of detailed clinical information, and a limited ability to control confounding...
  4. ncbi Aprotinin during coronary-artery bypass grafting and risk of death
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    N Engl J Med 358:771-83. 2008
    ..Aprotinin (Trasylol) is used to mitigate bleeding during coronary-artery bypass grafting (CABG). Accumulating evidence suggests that this practice increases mortality...
  5. ncbi Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Epidemiology 16:17-24. 2005
    ..We show how to assess the impact of confounding by factors not measured in Medicare claims data in a study of the association between selective COX2 inhibitors and acute myocardial infarction (MI)...
  6. ncbi Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Psychopharmacol 24:632-8. 2004
    ..Using survey data, we determined the magnitude of such bias and corrected the association between SSRI use and hip fractures accordingly...
  7. ncbi A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 58:98-102. 2005
    ..We sought to quantify the relative contributions of patient vs. physician factors to the decision to prescribe selective cyclooxygenase-2 (COX-2) inhibitors during the first 2 years of their availability...
  8. ncbi Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    Med Care 42:653-60. 2004
    ..Critics argued that drug plan savings are offset by administrative costs and increased spending on other health services...
  9. ncbi Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations
    Sebastian Schneeweiss
    Brigham and Women s Hospital and Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, 1620 Tremont St Suite 3030, Boston, MA 02120, USA
    BMJ 328:560. 2004
    ..To compare the results of a randomised and an observational evaluation of the same policy that restricted reimbursement for nebulised respiratory medications in adult patients in a community setting...
  10. ncbi Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Med Care 45:S131-42. 2007
    ..The goal of restricting study populations is to make patients more homogeneous regarding potential confounding factors and treatment effects and thereby achieve less biased effect estimates...
  11. ncbi Veteran's affairs hospital discharge databases coded serious bacterial infections accurately
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    J Clin Epidemiol 60:397-409. 2007
    ..We sought to test the ability of large health care utilization databases to accurately identify serious bacterial infections and opportunistic infections leading to hospital admission...
  12. ncbi Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 56:1754-64. 2007
    ..To assess the association between the initiation of anti-tumor necrosis factor alpha (anti-TNFalpha) therapy and the risk of serious bacterial infections in routine care...
  13. ncbi Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 021205, USA
    CMAJ 176:627-32. 2007
    ..We assessed the short-term mortality in a population-based cohort of elderly people in British Columbia who were prescribed conventional and atypical antipsychotic medications...
  14. ncbi Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
    Circulation 115:2128-35. 2007
    ....
  15. ncbi A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Clin Pharmacol Ther 79:379-88. 2006
    ..We evaluated the clinical and economic consequences of coverage restriction for 3 leading proton pump inhibitors (PPIs) in a large-scale natural experiment...
  16. ncbi Developments in post-marketing comparative effectiveness research
    S Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Pharmacol Ther 82:143-56. 2007
    ....
  17. ncbi Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Pharmacoepidemiol Drug Saf 15:291-303. 2006
    ..Confounders that require detailed information on clinical parameters, lifestyle, or over-the-counter medications are often not measured in such datasets, causing residual confounding bias...
  18. ncbi Methods in pharmacoepidemiology: time-varying drug effects revisited
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    Pharmacoepidemiol Drug Saf 15:93-4. 2006
  19. ncbi Understanding secondary databases: a commentary on "Sources of bias for health state characteristics in secondary databases"
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 60:648-50. 2007
  20. ncbi Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St Ste 3030, Boston, MA 02120, USA
    Am J Manag Care 13:445-52. 2007
    ....
  21. ncbi Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02120, USA
    Clin Pharmacol Ther 74:388-400. 2003
    ....
  22. ncbi Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts, USA
    CNS Drugs 23:171-80. 2009
    ..Nonrandomised studies on the causal effects of psychotropic medications may be biased by patient characteristics that are not fully adjusted...
  23. ncbi Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
    Sebastian Schneeweiss
    Department of Epidemiology, Harvard School of Public Health, Boston, Mass, USA
    CMAJ 166:737-45. 2002
    ..The objective of this study was to analyze the effect of reference-based pricing of angiotensin-converting enzyme (ACE) inhibitors on drug utilization, cost savings and potential substitution with other medication classes...
  24. ncbi On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective
    S Schneeweiss
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Health Policy 55:97-109. 2001
    ....
  25. ncbi Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance
    Sebastian Schneeweiss
    Divison of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave BLI 341, Boston, MA 02115, USA
    J Clin Epidemiol 55:833-41. 2002
    ..Results from nonrandomized comparisons of subgroups defined by their compliance to a policy change should generally be interpreted cautiously, and several biases should be explored...
  26. ncbi [An update of the German version of AEP (Appropriateness Evaluation Protocol): metric properties and practical experiences]
    S Schneeweiss
    Bayerischer Forschungsverbund Public Health, Ludwig Maximilians Universitat, Munchen
    Chirurg 72:196-8. 2001
    ..The majority of inappropriate care is due to poor documentation in medical records and management deficiencies during inpatient care...
  27. ncbi Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study
    Sebastian Schneeweiss
    Department of Medical Informatics, Biometry and Epidemiology, Pharmacoepidemiology Research Group, Ludwig Maximilians University, Munich, Germany
    Eur J Clin Pharmacol 58:285-91. 2002
    ..To estimate incidence rates of drug-related hospitalizations (DRHs) in a longitudinal population-based study with prospective event assessment...
  28. ncbi [Patient-centered evaluation of the health status in a longitudinal quality management system in the hospital]
    S Schneeweiss
    Harvard Medical School, Boston, USA
    Gesundheitswesen 63:205-11. 2001
    ..The objective was to assess the value of self-reported health status as an indicator of outcomes of acute hospital care, to identify potential practical limitations, and develop strategies for future applications...
  29. ncbi Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts
    Sebastian Schneeweiss
    Harvard Medical School, Brigham and Women s Hospital, Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA 02120, USA
    Pediatrics 125:876-88. 2010
    ..The objective of this study was to assess the risk of suicide attempts and suicides after initiation of antidepressant medication use by children and adolescents, for individual agents...
  30. ncbi First results from an intensified monitoring system to estimate drug related hospital admissions
    S Schneeweiss
    Department of Medical Informatics, Biometry and Epidemiology, Pharmacoepidemiology Research Group, Ludwig Maximilians University, Munich, Germany
    Br J Clin Pharmacol 52:196-200. 2001
    ..An intensified monitoring system was set up to identify drug related hospital admissions and estimate population-based incidences for commonly prescribed medications...
  31. ncbi Prescription duration after drug copay changes in older people: methodological aspects
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA
    J Am Geriatr Soc 50:521-5. 2002
    ..Reference pricing, a copayment for expensive medications above a fixed limit, for angiotensin-converting enzyme(ACE) inhibitors in older British Columbia residents, is used as a case example...
  32. ncbi Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 346:822-9. 2002
    ..Although reference pricing may reduce the costs of prescription drugs, there is concern that patients may switch to less effective medications or stop treatment...
  33. ncbi Pharmaceutical cost containment with reference-based pricing: time for refinements
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115, USA
    CMAJ 167:1250-1. 2002
  34. ncbi Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arch Gen Psychiatry 67:497-506. 2010
    ..This prompted a meta-analysis of trials in adults that found no overall increase in risk, but individual agents could not be studied...
  35. ncbi A basic study design for expedited safety signal evaluation based on electronic healthcare data
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Pharmacoepidemiol Drug Saf 19:858-68. 2010
    ....
  36. ncbi Costs of measuring outcomes of acute hospital care in a longitudinal outcomes measurement system
    Sebastian Schneeweiss
    Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Am J Med Qual 18:3-9. 2003
    ..This study should help hospital decision makers to estimate the necessary funding for outcomes measurement initiatives...
  37. ncbi Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Gigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    J Gen Intern Med 19:444-50. 2004
    ..We sought to evaluate and rank the performance of comorbidity scores across selected U.S. and Canadian elderly populations using health care utilization databases...
  38. ncbi Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
    S Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 021205, USA
    Aliment Pharmacol Ther 30:253-64. 2009
    ..There remain concerns about the safety of infliximab therapy in patients with inflammatory bowel disease (IBD)...
  39. ncbi [Corroboration of concurrent assessment of inappropriate hospitalization with retrospective evaluation based on patient records]
    S Schneeweiss
    Bayerischer Forschungsverbund Public Health
    Gesundheitswesen 62:207-10. 2000
    ..The objective was to assess the agreement of concurrent and retrospective assessment of inappropriate hospital use...
  40. ncbi Sensitivity analysis of the diagnostic value of endoscopies in cross-sectional studies in the absence of a gold standard
    S Schneeweiss
    Harvard Medical School, USA
    Int J Technol Assess Health Care 16:834-41. 2000
    ..The objective is to demonstrate an easily applicable method to assess the possible range of sensitivity, specificity, and predictive values of endoscopic procedures in the absence of a gold standard method...
  41. ncbi High-dimensional propensity score adjustment in studies of treatment effects using health care claims data
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Epidemiology 20:512-22. 2009
    ..Here, we develop and test an algorithm that empirically identifies candidate covariates, prioritizes covariates, and integrates them into a propensity-score-based confounder adjustment model...
  42. ncbi NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 021205, USA
    Pharmacoepidemiol Drug Saf 18:1134-42. 2009
    ....
  43. ncbi Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data
    S Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Epidemiol 154:854-64. 2001
    ..7% and 6.2%, respectively) for predicting mortality. Generalizability of results may be limited to an elderly, predominantly White population with equal access to state-funded health care...
  44. ncbi Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications
    Soko Setoguchi
    Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    J Am Geriatr Soc 56:1644-50. 2008
    ....
  45. ncbi Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Kidney Dis 46:1080-7. 2005
    ..However, little is known about the adequacy of adherence to these guidelines in elderly patients with diabetes and predictors of such appropriate ACE-inhibitor or ARB use...
  46. ncbi Improved comorbidity adjustment for predicting mortality in Medicare populations
    Sebastian Schneeweiss
    Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Health Serv Res 38:1103-20. 2003
    ..80. CONCLUSIONS: We conclude that in epidemiologic studies of the elderly, a modified diagnosis-based score using empirically derived weights provides improved adjustment for comorbidity and enhances the validity of findings...
  47. ncbi What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?
    S Schneeweiss
    Harvard School of Public Health, Boston, MA 02115, USA
    Health Policy 44:253-60. 1998
    ..The introduction of RBP in British Columbia in 1995-1997 and its computerized administrative health databases covering a large proportion of the population should give rise to a thorough analysis of this policy...
  48. ncbi Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis
    Niteesh K Choudhry
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Health Aff (Millwood) 26:186-94. 2007
    ..Our analysis suggests that covering combination therapy for such patients will save both lives and money...
  49. ncbi Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications
    Colin R Dormuth
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Ther 30:1038-50. 2008
    ..Objective: The aim of this study was to compare the effects of 2 recent cost-sharing policies on emergency hospitalizations due to chronic obstructive pulmonary disease, asthma, or emphysema (CAE), and on physician visits...
  50. ncbi Relationship between COX-2 specific inhibitors and hypertension
    Daniel H Solomon
    Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
    Hypertension 44:140-5. 2004
    ..1; 95% CI, 1.0 to 4.3). In this retrospective case-control study of patients aged > or =65 years, rofecoxib use was associated with an increased relative risk of new onset hypertension; this was not seen in patients taking celecoxib...
  51. ncbi Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, Mass 02120, USA
    Circulation 109:2068-73. 2004
    ..We studied the relative risk of acute myocardial infarction (AMI) among users of celecoxib, rofecoxib, and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit...
  52. ncbi Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Am Heart J 156:31-6. 2008
    ..Removing patient out-of-pocket drug costs may increase adherence, improve clinical outcomes, and even reduce overall health costs for high-risk patients. The existing data are inadequate to assess whether this strategy is effective...
  53. ncbi Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?
    Daniel H Solomon
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Med 115:715-20. 2003
    ..We examined the relative effects of patient risk factors for gastrointestinal toxicity, other patient characteristics, and physician prescribing preferences on the decision to prescribe a selective COX-2 inhibitor...
  54. ncbi Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma
    Colin R Dormuth
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Ther 28:964-78; discussion 962-3. 2006
    ..Evaluations of drug cost-sharing policies within the same population are needed for a fair comparison of different options...
  55. ncbi Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study
    K F Huybrechts
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, 02120 MA, United States
    BMJ 344:e977. 2012
    ..To assess risks of mortality associated with use of individual antipsychotic drugs in elderly residents in nursing homes...
  56. ncbi Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis
    Soko Setoguchi
    Divisions of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard MedicalSchool, Boston, MA 02130, USA
    Am Heart J 156:336-41. 2008
    ..Although TNFAs had significant benefits in treating rheumatoid arthritis (RA), little is known whether the drugs pose an increased risk of HF in older patients with RA...
  57. ncbi Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
    Daniel H Solomon
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 54:3790-8. 2006
    ..This study was undertaken to investigate the effects of various immunosuppressive medications on the risk of cardiovascular events among a group of older patients with RA...
  58. ncbi Identification of individuals with CKD from Medicare claims data: a validation study
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Am J Kidney Dis 46:225-32. 2005
    ..The validity of this approach to identify patients with CKD has not been sufficiently studied...
  59. ncbi Performance of a rheumatoid arthritis records-based index of severity
    Gladys Ting
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    J Rheumatol 32:1679-87. 2005
    ..Further tests of the RARBIS are recommended before it can be used as a tool to adjust for RA disease severity in performing epidemiologic studies on the safety of drugs...
  60. ncbi Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups
    Daniel H Solomon
    Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    Arthritis Rheum 59:1097-104. 2008
    ..There is substantial concern regarding the potential cardiovascular adverse effects of selective coxibs and nonselective NSAIDs, but many patients with arthritis experience important clinical benefits from these agents...
  61. ncbi Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02130, USA
    Arthritis Rheum 54:2757-64. 2006
    ..This study was undertaken to estimate the association between treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and development of cancer in patients with RA...
  62. ncbi Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications
    Colin R Dormuth
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Med Care 47:508-16. 2009
    ..We analyzed the impact on health plan spending of a switch in public drug insurance from full coverage to a prescription copayment (copay), and then to income-based deductibles plus coinsurance (IBD)...
  63. ncbi Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia
    Margreet S Duetz
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Ther 25:273-84. 2003
    ..However, these differences are unlikely to have meaningful clinical or economic consequences...
  64. ncbi Metric properties of the appropriateness evaluation protocol and predictors of inappropriate hospital use in Germany: an approach using longitudinal patient data
    Oliver Sangha
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Int J Qual Health Care 14:483-92. 2002
    ..Time since admission was the strongest predictor of inappropriate hospital use adjusted for length of stay, comorbidity, age, and gender...
  65. ncbi Refilling and switching of antiepileptic drugs and seizure-related events
    J J Gagne
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Pharmacol Ther 88:347-53. 2010
    ..19 (95% CI 0.35-3.99). Refilling the same AED prescription was associated with an elevated risk of seizure-related events whether or not the refill involved switching from a brand-name to a generic product...
  66. ncbi Patterns of cardiovascular risk in rheumatoid arthritis
    D H Solomon
    Division of Pharmacoepidemiology, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Ann Rheum Dis 65:1608-12. 2006
    ..This study investigated the relative risk of myocardial infarction, stroke and CVD mortality in adults with rheumatoid arthritis compared with adults without rheumatoid arthritis across age groups, sex and prior CVD event status...
  67. ncbi Use of comorbidity scores for control of confounding in studies using administrative databases
    S Schneeweiss
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Int J Epidemiol 29:891-8. 2000
    ..Our objective was to compare metrical and practical properties of published comorbidity scores for use in epidemiological research with administrative databases...
  68. ncbi Does knowledge of medication prices predict physicians' support for cost effective prescribing policies
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, USA
    Can J Clin Pharmacol 15:e286-94. 2008
    ..Years after implementation, these policies remain controversial among physicians...
  69. ncbi Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction
    Jerry Avorn
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
    Am J Cardiol 94:415-20. 2004
    ..Thus, in patients with AMI, earlier presentation to the hospital and more rapid initiation of thrombolysis could prevent significant decreases in functional status months after the initial infarct...
  70. ncbi Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records
    Yuka Kiyota
    Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, Mass USA
    Am Heart J 148:99-104. 2004
    ..1% vs 94.6%, P <.001). CONCLUSIONS: In this study, we observed high positive predictive values for a Medicare claims-based diagnosis of AMI and a diagnosis based on structured hospital record review...
  71. ncbi Evaluating uses of data mining techniques in propensity score estimation: a simulation study
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02130, USA
    Pharmacoepidemiol Drug Saf 17:546-55. 2008
    ....
  72. ncbi Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors
    Michael A Fischer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    N Engl J Med 351:2187-94. 2004
    ..To control these expenses, many state Medicaid programs have implemented prior-authorization requirements before coxibs can be prescribed. We evaluated the effect of such programs on the use of coxibs by Medicaid beneficiaries...
  73. ncbi Mortality following liver resection in US medicare patients: does the presence of a liver transplant program affect outcome?
    Elijah Dixon
    Harvard School of Public Health, Boston, Massachusetts, USA
    J Surg Oncol 95:194-200. 2007
    ....
  74. ncbi Angiotensin inhibition after myocardial infarction: does drug class matter?
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    J Gen Intern Med 21:1242-7. 2006
    ..Little is known about their relative use after MI in typical care settings, and about their relative effectiveness outside the clinical trial setting...
  75. ncbi Confounding control in healthcare database research: challenges and potential approaches
    M Alan Brookhart
    Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Med Care 48:S114-20. 2010
    ..Such reporting allows the reader to assess the sensitivity of the results to model assumptions that are often not supported by strong subject-matter knowledge...
  76. ncbi Clozapine use and risk of diabetes mellitus
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Psychopharmacol 22:236-43. 2002
    ..Additional data from pharmacoepidemiologic studies and randomized controlled trials are needed to exclude the possibility of residual confounding and ensure the appropriate use of this agent...
  77. ncbi Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome
    Jeremy A Rassen
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
    Circulation 120:2322-9. 2009
    ..Recent studies have raised concerns about the reduced efficacy of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may have overestimated the risk...
  78. ncbi Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharmacoepidemiology study of selective COX-2 inhibitors
    Susanna Jacobus
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 13:695-702. 2004
    ..Free drug samples are widely used in clinical practice. We were concerned about free sample drug utilization as a source of misclassification in pharmacoepidemiology research using claims data that may result in biased effect estimates...
  79. ncbi Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics
    Jeremy A Rassen
    Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Med Care 48:S83-9. 2010
    ..A large study on the safety of biologics required pooling of data from multiple data sources, but while extensive confounder adjustment was necessary, private, individual-level covariate information could not be shared...
  80. ncbi Use of the case-crossover design to study prolonged drug exposures and insidious outcomes
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Ann Epidemiol 14:296-303. 2004
    ..We investigated whether case-crossover methods can be used to study prolonged exposures and insidious outcomes...
  81. ncbi Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes
    Jeremy A Rassen
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA 02120, USA
    Am J Epidemiol 169:273-84. 2009
    ..Generalized method of moments estimation produced substantially the same results as the 2-stage logistic method. Few substantive differences among the methods were observed, despite their reliance on distinct assumptions...
  82. ncbi Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance
    Jeremy A Rassen
    Brigham and Women s Hospital, Boston, MA 02120, USA
    J Clin Epidemiol 62:1233-41. 2009
    ..As reduction in covariate imbalance may suggest increased IV validity, we sought to examine the covariate balance and instrument strength in 25 formulations of the PPP IV in two cohort studies...
  83. ncbi Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships
    Jeremy A Rassen
    Brigham and Women s Hospital, Boston, MA 02120, USA
    J Clin Epidemiol 62:1226-32. 2009
    ..It gives examples of instruments used in clinical epidemiology and concludes with an outline on estimation of effects...
  84. ncbi Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases
    Jeremy A Rassen
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Pharmacoepidemiol Drug Saf 19:848-57. 2010
    ..We sought to create a method to conduct pooled analyses while keeping information private and allowing for full confounder adjustment...
  85. ncbi Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention
    Jeremy A Rassen
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Eur Heart J 31:561-72. 2010
    ..Trials have indicated that bivalirudin is non-inferior to heparin with respect to death and repeat revascularization and may decrease the risk of major bleeds. The use of bivalirudin in routine care has not been evaluated...
  86. ncbi Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial
    Jerry Avorn
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Control Clin Trials 23:757-73. 2002
    ....
  87. ncbi A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods
    TIL STURMER
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 59:437-47. 2006
    ..Such analyses have been proposed to address confounding by indication, but there is little empirical evidence that they achieve better control than conventional multivariate outcome modeling...
  88. ncbi Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects?
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
    Med Care 45:S116-22. 2007
    ..We sought to explore the validity of physician-level IV in a comparative study of short-term mortality risk among elderly users of conventional versus atypical antipsychotic medications (APM)...
  89. ncbi Suboptimal antidepressant use in the elderly
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    J Clin Psychopharmacol 25:118-26. 2005
    ..Suboptimal antidepressant use remains common in the elderly, especially the use of inadequately intensive regimens. Interventions are needed to improve the quality and outcomes of antidepressant use in this vulnerable population...
  90. ncbi Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration
    TIL STURMER
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Am J Epidemiol 162:279-89. 2005
    ..66, 0.71). Application of PSC resulted in a more plausible hazard ratio of 1.06 (95% CI: 1.00, 1.12). Until the validity and limitations of PSC have been assessed in different settings, the method should be seen as a sensitivity analysis...
  91. ncbi Variable selection for propensity score models
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Am J Epidemiol 163:1149-56. 2006
    ..These simulation studies and other analytical results suggest that standard model-building tools designed to create good predictive models of the exposure will not always lead to optimal PS models, particularly in small studies...
  92. ncbi Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Arch Intern Med 167:847-52. 2007
    ....
  93. ncbi Instrumental variable analysis of secondary pharmacoepidemiologic data
    M Alan Brookhart
    Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02120, USA
    Epidemiology 17:373-4. 2006
  94. ncbi The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28
    Masayo Sato
    Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Arthritis Res Ther 8:R57. 2006
    ..The RARBIS has both face and convergent validity for patients with RA and relevant subgroups and may have application for medical records studies in patients with RA...
  95. ncbi Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Clin Epidemiol 59:18-25. 2006
    ..A statistical method is presented for attributing explained variation in patient care to different levels of aggregation in a multilevel model with the aim of prioritizing and targeting quality improvement interventions...
  96. ncbi Repeated hospitalizations predict mortality in the community population with heart failure
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02130, USA
    Am Heart J 154:260-6. 2007
    ..The impact of repeated heart failure (HF) hospitalization on mortality has not been studied for a large community population with HF. We aimed to characterize survival of patients in relation to the number of HF hospitalizations...
  97. ncbi Reference drug programs: effectiveness and policy implications
    Sebastian Schneeweiss
    Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Health Policy 81:17-28. 2007
    ..This paper summarizes the mechanism and rationale of RDPs, presents evidence of their economic effectiveness and clinical safety, and concludes with some practical implications of implementing RDP policies...
  98. ncbi Psychotropic medication use for behavioral symptoms of dementia
    Philip S Wang
    Department of Psychiatry, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Curr Neurol Neurosci Rep 6:490-5. 2006
    ..Also, although various psychotropic medications used for behavioral disturbances in dementia patients may be somewhat effective, they have been increasingly associated with important safety risks...
  99. ncbi Risk of death in elderly users of conventional vs. atypical antipsychotic medications
    Philip S Wang
    Department of Psychiatry, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    N Engl J Med 353:2335-41. 2005
    ..However, the advisory did not apply to conventional antipsychotic medications; the risk of death with these older agents is not known...
  100. ncbi Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives
    Philip S Wang
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Hypertension 46:273-9. 2005
    ..Highly prevalent, noncardiovascular conditions appear to deter use of antihypertensives in elderly with hypertension...
  101. ncbi Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients
    Evan L Thacker
    Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Drug Saf 29:1077-85. 2006
    ..The aim of this study was to determine whether initiation of therapy with AChEIs contributes to complications of chronic airways disorders in an elderly population...